EUVIMEDEUVIMED entdecken
Crossref

Refractory patients with favorable/intermediate‐risk acute myeloid leukemia benefit from azacytidine maintenance therapy following allogeneic hematopoietic stem cell transplantation

Yigeng Cao, Xinhui Zheng iD, Haixiao Zhang, Mingyang Wang, Wenwen Guo, Xin Chen, Weihua Zhai, Jialin Wei, Donglin Yang, Yong Huang, Aiming Pang, Sizhou Feng und 2 weitere

Hematological Oncology · 2024-01 · 42 (1)

DOI: 10.1002/hon.3232 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hematological Oncology, online erschienen am 04.10.2023. Verfasst von Yigeng Cao und 13 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute …. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 13 Literaturangaben. Gefördert von: Natural Science Foundation of Tianjin Municipality, Key Project of Tianjin Natural Science Foundation, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recurrence following allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is the major cause of treatment failure in patients with myeloid malignancy. Azacytidine (AZA) maintenance is a promising therapy to prevent relapse and improve survival. We conducted a prospective, one‐arm study involving 78 patients with myeloid malignancy at a high risk of recurrence who were enrolled between September 2019 and April 2022. Furthermore, 102 matched historical controls were selected using propensity score matching. With a median follow‐up time of 19.6 (3.5–91.7) months, AZA maintenance therapy significantly improved relapse‐free survival (RFS; log‐rank test, p = 0.01). The AZA and control groups had a 1‐year RFS of 87.7% (95% confidence interval [CI], 0.80–0.96) and 72.2% (95% CI, 0.64–0.82), respectively, with a hazard ratio (HR) of 0.21 (95% CI, 0.09–0. 47; p < 0.01). There were no grade 4 adverse effects or deaths related to AZA. Refractory patients with favorable/intermediate‐risk acute myeloid leukemia (AML) benefited more from AZA maintenance therapy than those with adverse‐risk AML according to the European Leukemia Net guidelines (RFS in favorable/intermediate‐risk AML, HR = 0.29, 95% CI, 0.11–0.79; RFS in adverse‐risk AML, HR = 0.57, 95% CI, 0.21–1.6; p for interaction = 0.03). Our findings suggest that AZA maintenance therapy following allo‐HSCT was safe and could reduce the incidence of relapse, particularly for refractory patients with favorable/intermediate‐risk AML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteHematopoietic Stem Cell TransplantationHumansAzacitidineProspective StudiesTransplantation, HomologousChronic DiseaseRecurrenceRetrospective Studies

Stichwörter der Autor:innen

azacytidinehematopoietic stem cell transplantation

Substanzen

Azacitidine

Autor:innen und Institutionen

  • State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc…

ORCID-Profile: Xinhui Zheng, Erlie Jiang

Förderung

  • Natural Science Foundation of Tianjin Municipality
  • Key Project of Tianjin Natural Science Foundation
  • National Natural Science Foundation of China
  • Haihe Laboratory of Cell Ecosystem Innovation Fund
  • CAMS Innovation Fund for Medical Sciences

Zitieren

APA

Cao, Y., Zheng, X., Zhang, H., Wang, M., Guo, W., Chen, X., Zhai, W., Wei, J., Yang, D., Huang, Y., Pang, A., Feng, S., Jiang, E., & Han, M. (2024). Refractory patients with favorable/intermediate‐risk acute myeloid leukemia benefit from azacytidine maintenance therapy following allogeneic hematopoietic stem cell transplantation. Hematological Oncology, 42(1). https://doi.org/10.1002/hon.3232

Vancouver

Cao Y, Zheng X, Zhang H, Wang M, Guo W, Chen X, et al. Refractory patients with favorable/intermediate‐risk acute myeloid leukemia benefit from azacytidine maintenance therapy following allogeneic hematopoietic stem cell transplantation. Hematological Oncology. 2024;42(1). doi:10.1002/hon.3232

BibTeX
@article{Cao2024,
  author = {Cao, Yigeng and Zheng, Xinhui and Zhang, Haixiao and Wang, Mingyang and Guo, Wenwen and Chen, Xin and Zhai, Weihua and Wei, Jialin and Yang, Donglin and Huang, Yong and Pang, Aiming and Feng, Sizhou and Jiang, Erlie and Han, Mingzhe},
  title = {Refractory patients with favorable/intermediate‐risk acute myeloid leukemia benefit from azacytidine maintenance therapy following allogeneic hematopoietic stem cell transplantation},
  journal = {Hematological Oncology},
  year = {2024},
  volume = {42},
  number = {1},
  doi = {10.1002/hon.3232}
}
Kostenlos starten →